
Data Collection Instrument and Procedure for Systematic Reviews in the *Guide to Community Preventive Services*

Stephanie Zaza, MD, MPH, Linda K. Wright-De Agüero, PhD, MPH, Peter A. Briss, MD, Benedict I. Truman, MD, MPH, David P. Hopkins, MD, MPH, Michael H. Hennessy, PhD, MPH, Daniel M. Sosin, MD, MPH, Laurie Anderson, PhD, Vilma G. Carande-Kulis, PhD, Steven M. Teutsch, MD, MPH, Marguerite Pappaioanou, DVM, PhD, Task Force on Community Preventive Services

Introduction: A standardized abstraction form and procedure was developed to provide consistency, reduce bias, and improve validity and reliability in the *Guide to Community Preventive Services: Systematic Reviews and Evidence-Based Recommendations* (the *Guide*).

Data Collection Instrument: The content of the abstraction form was based on methodologies used in other systematic reviews; reporting standards established by major health and social science journals; the evaluation, statistical and meta-analytic literature; expert opinion and review; and pilot-testing. The form is used to classify and describe key characteristics of the intervention and evaluation (26 questions) and assess the quality of the study's execution (23 questions). Study procedures and results are collected and specific threats to the validity of the study are assessed across six categories (intervention and study descriptions, sampling, measurement, analysis, interpretation of results and other execution issues).

Data Collection Procedures: Each study is abstracted by two independent reviewers and reconciled by the chapter development team. Reviewers are trained and provided with feedback.

Discussion: What to abstract and how to summarize the data are discretionary choices that influence conclusions drawn on the quality of execution of the study and its effectiveness. The form balances flexibility for the evaluation of papers with different study designs and intervention types with the need to ask specific questions to maximize validity and reliability. It provides a structured format that researchers and others can use to review the content and quality of papers, conduct systematic reviews, or develop manuscripts. A systematic approach to developing and evaluating manuscripts will help to promote overall improvement of the scientific literature.

Medical Subject Headings (MeSH): data abstraction, evaluation, study design, study quality (Am J Prev Med 2000;18(1S):44–74) © 2000 American Journal of Preventive Medicine

Introduction

The independent, non-federal Task Force on Community Preventive Services (the Task Force) will make recommendations about

From the Division of Prevention Research and Analytic Methods, Epidemiology Program Office (Zaza, Wright-De Agüero, Briss, Truman, Hopkins, Anderson, Carande-Kulis), Centers for Disease Control and Prevention (CDC); Division of STD Prevention, National Center for HIV, STD, and TB Prevention (Hennessy); National Center for Injury Prevention and Control (Sosin); Merck & Co., Inc. (Teutsch), West Point, Pennsylvania.

The names and affiliations of the Task Force members are listed on page v of this supplement and at <http://www.thecommunityguide.org>

Address correspondence and reprint requests to: Stephanie Zaza, MD, MPH, Community Preventive Services Guide Development Activity, Epidemiology Program Office, MS-K-73, Centers for Disease Control and Prevention, 4770 Buford Highway, Atlanta, GA 30341.

At the time this work was performed, Dr. Pappaioanou was with the Division of Prevention Research and Analytic Methods, CDC, Atlanta, Georgia. Her current affiliation is with the Office of Global Health, CDC, Atlanta, Georgia.

health promotion and disease prevention interventions in the *Guide to Community Preventive Services: Systematic Reviews and Evidence-Based Methods* (the *Guide*).¹ These recommendations will be based on systematic reviews of the evidence of effectiveness, other positive and negative effects of the interventions, applicability of the effectiveness information, economic evaluations and barriers to implementation of the interventions.² Fifteen topics are currently being reviewed, and each chapter will cover a single topic and include reviews for 10–20 interventions.^{2,3} A multidisciplinary team (i.e., the chapter development team) coordinates development of each chapter and consists of Task Force members, a coordinating scientist, and several topic experts.² The chapter development team defines the scope and intent of each chapter and selects a set of interventions for inclusion in the chapter using pre-defined criteria.² To evaluate the effectiveness of the

intervention, the team conducts a systematic review of the scientific literature. The systematic review methods include: identifying the potential links between an intervention and relevant outcomes, using specific inclusion criteria to search for studies, evaluating effectiveness of the interventions, and evaluating the content and quality of each study.²

Conducting systematic reviews for development of the *Guide* involves multiple coordinating scientists and participants, reviews of interventions in highly variable topics (e.g., sexual behavior, cancer, motor vehicle occupant injuries), a range of intervention types (e.g., education, environmental change, policy development), and the inclusion of all types of comparative study designs (e.g., experimental studies with allocated control groups or observational studies with concurrent or historical control groups). These features of the development process have the potential for introducing inconsistency into the *Guide*. The use of a standardized data collection instrument and procedure is one way to reduce inconsistencies within and between chapters.

In this paper we describe the instrument and procedure used to collect and evaluate data from individual studies of intervention effectiveness, a key step in the methods used to develop the *Guide*. The form illustrates the Task Force's approach to categorizing information about study design, content, and quality of the scientific literature. This approach will be useful to others for the purposes of reading the scientific literature, writing scientific manuscripts, designing evaluation studies or teaching epidemiology and evaluation methods.

Data Collection Instrument

In developing the data collection instrument, we considered its six main purposes:

- Tracking the article review process. The form collects information needed to monitor the status of screening, reviewing and summarizing of each article by multiple reviewers.
- Developing tables that summarize the body of evidence. The form captures detailed descriptive data about the intervention and evaluation; this data is used to develop summary evidence tables for each intervention.^{2,4}
- Classifying other key characteristics of the intervention and evaluation. Additional descriptive data is collected to construct a database that will be available as a resource for intervention planners and researchers.
- Assessing the quality of the study's execution. Reviewers identify and document the threats to validity of each study due to faulty execution or poor measurement. This information is used as a criterion for continued inclusion of the study in the body of evidence for an intervention.²
- Identifying other pertinent information. The form captures information about the intervention's applicability in settings and populations other than that studied by the investigators, economic data about the intervention, and other positive or negative effects of the intervention.
- Identifying additional studies that should be reviewed. To help ensure that no relevant studies are left out, reviewers read the bibliographies in each study they review and list relevant articles for potential inclusion in the review process.

The content of the form was developed by reviewing methodologies from other systematic reviews (e.g., those used by the Cochrane Collaboration); reporting standards established by major health and social science journals; the evaluation, statistical and meta-analytic literature; and by soliciting expert opinion and review of draft versions of the form.⁵⁻¹⁵ Based on this literature review and the specific needs of the *Guide*'s review process, we determined which data elements to include in the form. During early development of the form, chapter development team members and others pilot-tested the form for clarity and reliability of responses between reviewers. The form was revised and used to develop several chapters. The abstraction form was further revised based on this early experience, the initiation of development of chapters in different subject matters, input from reviewers, review by coordinating scientists with training in multiple scientific disciplines, and interviews with coordinating scientists to identify inconsistency in interpretation of questions. The revision aimed to clarify ambiguous or confusing questions, expand instructions and examples to guide reviewers, improve the format of the form, cross reference questions, and refine the quality of execution categories.

The abstraction form (see Appendix) is constructed as a booklet with instructions appearing on the left-hand pages for corresponding questions on the right-hand pages. The form is 26 pages in length, including a cover page with tracking information, the instructions and the response pages. It contains 26 questions regarding the content of the study, and 23 questions regarding the quality of execution of the study. Two to three hours are required to read each paper and abstract data using the form.

The questions are compiled in three sections: classification information, descriptive information, and quality of execution information. Classification information is completed by the chapter development team to focus the reviewer's evaluation of the study. This first section includes a study design algorithm that allows each study to be included in only one study design category (see Appendix, page 74). The suitability of the study design for evaluating effectiveness of an intervention is assessed and rated separately (i.e., not using the abstrac-

tion form itself).² In addition, intervention components are categorized into major groupings for the purposes of tracking and searching. Finally, relevant outcomes to be collected are determined by the chapter development team according to the conceptual framework for the chapter. These responses are checked and corrected, if necessary, by the reviewer.

The second section of the form allows the reviewer to document the methods and results of the study. First, reviewers are asked to describe the intervention (what, how, where and to whom); theories supporting the intervention; the type of organization implementing the intervention; and any intervention provided to comparison groups. Second, reviewers are guided through a series of questions about the characteristics of the evaluation study itself:

- the evaluation site, including location, population density, and setting (if different from implementation of the intervention);
- the study population (i.e., sample sizes and method of selection, assessment of exposure to the intervention, demographic and risk factor information);
- any other populations described by the authors that could be affected by the intervention; and
- measurement of outcome in and other characteristics of the study population.

Third, reviewers follow a structured format to report the study results, including the effect measures, the data for each intervention and comparison arm reported in the study, software used, analytic methods, hypothesis testing and study power. Fourth, reviewers collect information about other key issues reported in the study that might be of future use to the chapter development team and references that might meet the inclusion criteria for the review.

The third section of the abstraction form documents the reviewer's judgment about the quality of execution of the study. Six categories (descriptions, sampling, measurement, analysis, interpretation of results and other) assess specific threats to the validity of the study (Table 1). Because these questions are difficult to interpret consistently and are prone to be answered subjectively, the instructions provide explicit decision rules (e.g., what to consider, what not to consider) and specific examples of how to answer the question in various circumstances. Reviewers are asked to provide an explanation for responses to each question.

Quality of execution is assessed based on the descriptive data collected from the report. To assist reviewers, the questions in this section of the form refer to the relevant questions in the first two sections. For example, to determine the adequacy of the study population sample (see Appendix, Section III, Questions 2A–2D), the reviewer is referred back to the questions in the second section of the form that elicit the study popu-

Table 1. Categories of questions that assess potential threats to the validity of each study, data collection instrument, *Guide to Community Preventive Services*

Categories	Potential threats to validity addressed by the category
Descriptions Example: Is the intervention well described?	Bias introduced by failure to maintain integrity of the intervention
Sampling Example: Did the authors specify the screening criteria for study eligibility?	Selection bias
Measurement Example: Were the exposure and outcome measures valid and reliable?	Measurement biases <ul style="list-style-type: none"> • observer/interviewer • self-report • recall • others Misclassification bias <ul style="list-style-type: none"> • exposure • outcome
Analysis Example: Did the authors conduct an appropriate analysis by conducting statistical testing, controlling for repeated measures, etc.	Analytic biases <ul style="list-style-type: none"> • repeated measures • differential exposure • design effects • cross-level bias • others
Interpretation of results Example: Did the authors correct for controllable confounders?	Attrition bias Confounding Secular trends All others

lation description (see Appendix, Section II, Questions 11–17), sampling method (see Appendix, Section II, Questions 11A and 11B), and sample size (see Appendix, Section II, Question 11B).

Each type of study design has particular issues that can influence quality of execution scoring. To evaluate the quality of studies using different designs, questions were developed that evaluate a general concept and instructions provide specific examples to assist the reviewer. For example, two general questions about validity and reliability were included to assess potential problems with outcome measurement (Table 2). For a randomized trial, failure to blind observers or interviewers would result in a limitation for outcome measure validity. For a paper with a time series design, blinding would not be considered in assessing validity of the outcome measure, but other issues relevant to validity would be considered. For all questions in the quality of execution section, if the quality issue relevant to the study design is not reported in the paper being reviewed, the paper gets a limitation for that question.

Table 2. Questions from the data collection instrument, *Guide to Community Preventive Services*

- Were the outcome and other independent (or predictor) variables valid measures of the outcome of interest? The authors should have reported one or more of the following:
- Clear definition of the outcome variable.
 - Measurement of the outcome in different ways. Example: Correlational analysis between measured outcomes to demonstrate convergent (i.e., 2 or more measures reflect the same underlying process) or divergent validity (i.e., 2 or more measures reflect different dimensions). An example of the former is that 5 items on self-efficacy correlate highly with each other; an example of the latter is that self-efficacy measures do not correlate highly with attitude measures.
 - Citations or discussion as to why the use of these measures is valid. Example: see above
 - Other. Example: If authors fail to blind observers/interviewers to treatment vs. comparison group, when applicable, the answer to this question should be “no.”
- Were the outcome and other independent (or predictor) variables reliable (consistent and reproducible) measures of the outcome of interest? The authors should have reported one or more of the following:
- Measures of internal consistency. Example: see 3B
 - Measures of the outcome in different ways. Example: see 3B and 3C (above).
 - Considered consistency of coding scoring or categorization between observers (e.g., inter-rater reliability checks) or between different outcome measures. Example: percent agreement, Kappa
 - Considered how setting and sampling of study population might affect reliability.
 - Citations or discussion as to why the use of these measures is reliable. Example: see 3B.
 - Other

Response options:	Yes	No	N/A	Related questions
Were the outcome and other independent (or predictor) variables: Valid?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	I/10
Reliable (consistent and reproducible)?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	II/8, 9, 10, 18, 20

Data Collection Procedures

Data is collected from each study by two independent reviewers. If the reviewers report different information for a question, the chapter development team reconciles the two reviews. Members of the chapter development team, graduates of Masters of Public Health degree programs, doctoral candidates and physicians in preventive medicine training programs serve as reviewers. Selection of reviewers is based on experience in content areas, experience in conducting evidence-based reviews and expertise in research design and methodology. Training is conducted in three phases. First, background information is provided on the *Guide* development process and methodology; a sample study with a completed form and summary evidence table is included. Second, each applicant is asked to assess a study that has been previously reviewed by the chapter development team. This initial review is then discussed in detail with the applicant, with additional instruction for interpreting questions provided by the coordinating scientist. Third, the selected applicants review groups of papers on related interventions with continuing feedback provided by the chapter development team.

Discussion

Systematic reviews of four topics (tobacco use, physical activity, motor vehicle occupant injury and vaccine preventable diseases) in the *Guide* have been conducted using the data collection instrument and procedures. Over 400 papers with designs as varied as randomized controlled trials, time series studies and cross-sectional

studies have been reviewed by more than 40 reviewers, all of whom have provided feedback and suggestions for improving the instructions and format of the form.

The development of a standardized abstraction form for the series of systematic reviews as wide ranging as those included in the *Guide* presented two major challenges. We sought to develop a form with enough flexibility to allow the evaluation of papers with different study designs and intervention types. We were concerned that questions and instructions that are too directive and specific would lack the flexibility necessary to address relevant questions for different subject areas and study designs. However, we needed to balance flexibility with the risk of losing specificity in how questions are asked, potentially compromising interrater and interchapter reliability. We also had to balance the need for simplicity and brevity of the form with the need for detailed information.

We attempted to balance these issues through an iterative process of designing questions and instructions, using those to review papers in different subject areas and with different study designs, assessing the responses in the review of papers, eliciting feedback from reviewers and revising the questions and instructions. In addition, the actual use of data from each question on the form was compared to its proposed use; questions were removed from the form if they did not provide material that was included in evidence tables, information necessary to assess the quality of the study's execution, ancillary information for use in development of the chapter or material that will be included in the *Guide* database.

The abstraction form provides the basis for drawing conclusions about individual studies. In any systematic review process, the individual studies serve as the data points for resolving research questions. The review and evaluation of each study is a qualitative analysis in and of itself. Decisions on what to abstract and how to summarize are all analytic choices that influence what conclusions are drawn on the execution of the study and its effectiveness.¹⁶ Validity and reliability of the abstraction form are crucial to confidence in the results of the reviews.

The face and content validity of the form are strengthened by the method of its development: the form was modeled on previous similar documents, and was reviewed and revised in an iterative process that included expert review, checks on consistency of interpretation and coding, and examination of products resulting from the reviews (e.g., evidence tables and recommendations). In addition, the content of the form was compared to that in similar instruments used in other efforts and quality criteria used by various journals to evaluate papers for publication. This validation process focused on clarity, completeness, and relevance of the questions on the form to key concepts addressed in each section. Future versions of the form will be based on continued review of the validity of the form. For example, a remaining research question is how the rating of each quality category (i.e., Part III of the form) influences the assessment of a body of evidence on effectiveness of the intervention and resulting recommendations.

In addition to assessing the validity of the form, the reliability of responses between reviewers was assessed on early versions of the form.^a Special attention was paid to questions with lower reliability during revision of the form. Although this analysis has not been repeated for the final version of the form, the improvements to the instructions and formatting of the form should improve inter-rater reliability.

In addition to improving the validity and reliability of reviews for the *Guide*, this standardized abstraction form provides a structured format that researchers and other readers of the scientific literature can use to review the content and quality of papers, conduct other evidence-based reviews, or develop manuscripts for submission to peer-reviewed journals. Improving the public health literature and evaluation methodology is a goal of the Task Force. To promote such improve-

^a Reliability between abstractors reviewing the same paper was assessed for individual questions for two chapters: motor vehicle occupant injuries and vaccine preventable diseases. Percent agreement between abstractors for descriptive questions ranged from 34.5% to 96.7% (median = 75.0%). Percent agreement between abstractors for quality of execution questions ranged from 65.2% to 85.6% (median = 79.5%).

ment, the form was developed within the public domain and can be copied and used freely. An electronic version of the form is available on the internet at <http://web.health.gov/communityguide> or at <http://www.elsevier.com/locate/ajpmonline> or by contacting the author.

The authors gratefully acknowledge David Atkins, MD, MPH (Agency for Health Care Policy Research); Donna Higgins, PhD (CDC); David McQueen, PhD (CDC); Mike Stoto, PhD (George Washington University); and Steven Woolf, MD, MPH (Medical College of Virginia) for their helpful reviews, comments and suggestions for improvements to the data collection instrument.

References

1. Truman BI, Smith-Akin CK, Hinman AR, et al. and the Task Force on Community Preventive Services. Developing the Guide to Community Preventive Services—overview and rationale. *Am J Prev Med* 2000;18(suppl 1):18–26.
2. Briss PA, Zaza S, Pappaioanou M, et al. and the Task Force on Community Preventive Services. Developing an evidence-based Guide to Community Preventive Services—methods. *Am J Prev Med* 2000;18(suppl 1):35–43.
3. Zaza S, Lawrence RS, Mahan CS, et al. and the Task Force on Community Preventive Services. Scope and organization of the Guide to Community Preventive Services. *Am J Prev Med* 2000;18(suppl 1):27–34.
4. Shefer A, Briss PA, Rodewald L, et al. Improving immunization coverage rates: an evidence-based review of the literature. *Epidemiol Rev* 1999;21:96–142.
5. Stool SE, Berg AO, Berman S, et al. Otitis media with effusion in children. Guideline Technical Report Number 12, AHCPR Publication No. 95–0621. Rockville, MD: Agency for Health Care Policy Research, Public Health Service, U.S. Dept. of Health and Human Services, July 1994.
6. Canadian Task Force on the Periodic Health Examination. Canadian guide to clinical preventive health care. Ottawa: Canada Communication Group, 1994.
7. Gyorkos TW, Tannenbaum TN, Abrahamawicz M, Oxman AD, Scott EAF, Millson ME, et al. An approach to the development of practice guidelines for community health interventions. *Can J Public Health* 1994;85(suppl 1):S8–S13.
8. Hennessy M. Evaluation. In: Stroup DF, Teutsch SM, eds. *Statistics and public health: quantitative approaches to public health problems*. New York: Oxford University Press, 1998:193–219.
9. Kafadar K, Andrews JS. Investigating health effects and hazards in the community. In: Stroup DF, Teutsch SM, eds. *Statistics and public health: quantitative approaches to public health problems*. New York: Oxford University Press, 1998:93–122.
10. The Joint Committee on Standards for Educational Evaluation. *The program evaluation standards: how to assess evaluations of educational programs*. 2 ed. Thousand Oaks, CA: Sage Publications, 1994.
11. Cooper H, Hedges LV, eds. *The handbook of research synthesis*. New York: Russell Sage Foundation, 1994.
12. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al. Improving the quality of reporting of randomized controlled trials: the CONSORT statement. *JAMA* 1996;276:637–9.
13. US Preventive Services Task Force. *Guide to Clinical Preventive Services*. 2 ed. Alexandria, VA: International Medical Publishing, 1996.
14. Sackett DL, Richardson WS, Rosenberg W, Haynes RB. *Evidence-based medicine: how to practice and teach EBM*. New York: Churchill Livingstone, 1997.
15. *HIV Prevention Among Drug Users: A Resource Book for Community Planners and Program Managers*. Washington, DC: Academy for Educational Development, 1997.
16. Miles MB, Huberman AM. *Qualitative data analysis: an expanded sourcebook*. Thousand Oaks, CA: Sage Publications, 1994.

Appendix

Data Abstraction Form

Introduction

This data abstraction form is a standard instrument used to systematically collect data from scientific reports in development of the *Guide to Community Preventive Services* (the Guide). You and one other abstractor will review each paper by using this form. After members of the chapter development team reconcile any differing responses, the data from these forms will be used in evidence databases and tables. Recommendations in the Guide will be based on this evidence. The data required to fill in the form will provide information on the intervention under study, evaluation setting and study population, outcomes, results, and study quality.

The three sections of the form consist of **Part I. Classification Information**, which is filled out by the chapter development team and reviewed and edited by the abstractors; **Part II. Descriptive Information** about the intervention, evaluation study characteristics, measurement of outcomes, and results; and **Part III. Study Quality** about the execution of the study. On average, it should take you 2 to 3 hours to read a paper and fill out the form. A note on formatting: Some of the questions are included in tables or text boxes. These boxes are included to ease readability of the form, NOT to limit the amount of information you can provide. If you need additional space, feel free to use the margins, other available space, or additional pages to write your answers. Also note that only the data sheets are to be completed; the instruction pages provide details and examples to help you respond to questions on the facing data sheet pages.

We have provided examples and commentary in italics throughout the instructions to help you do consistent reviews. However, if any questions arise during your reviews, feel free to contact the chapter development team to clarify any issues that are confusing.

To return the form, fax **ONLY this cover sheet and the pages labeled "Data Sheet" in the upper right hand corner (i.e., the right-hand pages)**. *Note:* If you elect to mail rather than FAX your forms, copy the cover page and the data sheets and mail those to us; retain the original form in your files until the chapter development team has contacted you to review the evidence tables and reconcile any differences from those of the second abstractor.

Notes:

1. For all multiple-choice questions, checking more than one response is acceptable and appropriate.
2. Indicate page or table numbers where data are located in the paper to aid checking the information.

Tracking Information:

Topic: _____

Subtopic: _____

Intervention title: _____

Reviewer Name: _____

Tracking Number: _____

Citation: _____

Study type:

Published article

Technical report

Unpublished dissertation/thesis

Abstract/presentation

Book/book chapter

Other *Specify:* _____

For questions 1-3, review carefully the information provided and check the appropriate box in the gray shaded area to indicate if the chapter development team's assessment is correct or incorrect. If the assessment is incorrect, provide the correct information.

1. **Study Design:** See figure on back page: "Study Design Algorithm"
2. **Intervention Components:** Many interventions have more than one component. Check all that apply.

Provision of information only: These interventions try to change knowledge, attitudes or norms. Intervention methods might involve instruction (e.g., classes, assemblies), small media (e.g., brochures, leaflets, posters, letters, newsletters) or large media (e.g., television, radio, newspapers, billboards). For these interventions, also note the target population.

Behavioral interventions: These interventions try to change behaviors by providing necessary skills or materials. Intervention methods might involve modeling or demonstration, role playing, participatory skill development, individual benchmarking (i.e., goal-setting and achievement), providing feedback, providing incentives or penalties, or providing materials necessary to perform the desired behavior (e.g., condoms, car seats). For these interventions, also note the target population.

Environmental interventions: These interventions try to change the physical and or social environment to promote health or prevent disease. Interventions in the physical environment might involve adding to (e.g., fluoride in water systems), changing (e.g., resilient playground surfaces), or subtracting from (e.g., lead in gasoline and paint) the environment. Interventions in the social environment might include increasing employment opportunities (e.g., welfare-to-work programs) or development of community coalitions to change social systems (e.g., Detroit's "Angel's Night" anti-arson program).

Legislation/Regulation/Enforcement: These interventions try to change behaviors or alter disease risk factors by legislating particular behaviors, regulating risk factors, and enforcing those laws and regulations.

Examples:

- *Mandatory seat belt use laws*
- *School vaccination laws*
- *Increasing tobacco taxes*

Clinical: These interventions aim to increase access to and assurance of clinical care (patient-focused).

Public health or medical care system interventions: These interventions aim to change the public health or clinical care systems to increase or improve delivery of services (system-focused).

Examples:

- *Development of registries and surveillance systems*
- *Incentives to develop hospital policies for standing orders for vaccine administration*

- 2b. Was the intervention part of a larger intervention effort?

Example: a school based anti-drug educational program was implemented as a segment of a multi-state comprehensive health risk behavior modification program and is evaluated in this study.

3. **Primary Outcome Measure(s):** How was (were) the outcome measure(s) defined? Check all that apply and provide the definition used by the authors.

- Behavior (e.g., *observed correct use of child-restraint devices by children aged ≤ 5 years*)
- Other intermediate or mediating outcome: an outcome that precedes or is correlated with one or more health outcomes and stems from exposure to a determinant (e.g., *possession of child-restraint devices*)
- Non-fatal health outcome (e.g., *non-fatal motor vehicle occupant injury rates among children aged ≤ 5 years*).
- Severity of illness/injury (e.g., *injury severity scores among children ≤ 5 years injured in motor vehicle crashes*).
- Death (e.g., *fatal motor vehicle occupant injury rates among children ≤ 5 years*).
- Surrogate outcome: an outcome that is considered to be a proxy for health or other outcomes of interest (e.g., *number of citations issued for non-use of child-restraint devices when required by law*).

1. Study Design:

- | | |
|--|---|
| <input type="checkbox"/> Randomized trial (experiment) | <input type="checkbox"/> Retrospective cohort study |
| <input type="checkbox"/> Individual <input type="checkbox"/> Group | <input type="checkbox"/> Case-control study |
| <input type="checkbox"/> Non-randomized "trial" (with ≥ 1 comparison group) | <input type="checkbox"/> Time series study |
| <input type="checkbox"/> Individual <input type="checkbox"/> Group | <input type="checkbox"/> Before-after study |
| <input type="checkbox"/> Prospective cohort study | <input type="checkbox"/> Cross-sectional study |
| <input type="checkbox"/> Other designs with concurrent comparison groups | <input type="checkbox"/> Non-comparative study |
| <input type="checkbox"/> Other <i>Specify:</i> _____ | |

- The study design indicated by the chapter development team is correct.
- The study design indicated by the chapter development team is incorrect or insufficient. I have added to or corrected the above information.

2. Intervention Components: (Check all that apply)

- | | | | |
|--|---|--|---|
| <input type="checkbox"/> Provision of information only | <input type="checkbox"/> General | <input type="checkbox"/> High-risk group | <input type="checkbox"/> Professional group |
| <input type="checkbox"/> Behavioral intervention | <input type="checkbox"/> General | <input type="checkbox"/> High-risk group | <input type="checkbox"/> Professional group |
| <input type="checkbox"/> Environmental intervention | <input type="checkbox"/> Physical environment | | <input type="checkbox"/> Social environment |
| <input type="checkbox"/> Legislation/Regulation/Enforcement | | | |
| <input type="checkbox"/> Clinical | | | |
| <input type="checkbox"/> Public health or medical care system intervention | | | |
| <input type="checkbox"/> Other <i>Specify:</i> _____ | | | |
| <input type="checkbox"/> This paper does not evaluate an intervention. | | | |

- The intervention components indicated by the chapter development team are correct.
- The intervention components indicated by the chapter development team are incorrect or insufficient. I have added to or corrected the above information.

2b. Was the intervention part of a larger intervention effort?

- Yes (*describe in Part II, question 1*)
- No

3. Primary Outcome Measure(s)

- Behavior *Describe:* _____
- Other intermediate or mediating outcome *Describe:* _____
- Non-fatal health effect *Describe:* _____
- Severity of illness/injury *Describe:* _____
- Death *Describe:* _____
- Surrogate outcome *Describe:* _____

- The outcome measure(s) indicated by the chapter development team is (are) correct.
- The outcome measure(s) indicated by the chapter development team is (are) incorrect or insufficient. I have added to or corrected the above information.

A. Description of the Intervention

1. Use the following parameters to describe the intervention. The requested information might not be reported in the paper; if so indicate whether it is "Not available" or "Not applicable." Provide as much of this information as possible, and **include other relevant aspects of the intervention as necessary.**
 - **What is the proposed intervention?** Describe the level or scale of focus (i.e., individual, family, group, community, or general public). Describe the services, materials, and other information that were delivered, or the policy or law that was enacted (include information about enactment, implementation, and enforcement).
 - **How is the intervention being delivered?** Describe who delivered the intervention (e.g., health professional, volunteer, peer), how they were trained, and how they were assigned. Describe how the target population learned about the intervention. Describe the time period, frequency, and duration of the intervention. Describe the scope of the intervention (i.e., how many members of the target group(s) were reached by the intervention). Describe the extent of coordination with other agencies/organizations and the target community.
 - **Who is being targeted?** Again, this might be broader than the population that was studied in the evaluation; briefly describe the characteristics of the target population.
 - **Where is the intervention being delivered?** The intervention might be delivered in a particular type of setting or community-wide. This parameter should be described for the intervention as it was implemented, which might be in a setting broader than that which was studied in the evaluation.

Examples:

- **What:** Individual parents received 1 or 2 personalized postcard reminders signed by their pediatrician to remind them their children were due for MMR vaccination and to present the adverse health consequences of being unvaccinated. If no response was made to postcard reminders, a public health nurse made up to 3 attempts to visit the family at their home to provide vaccination; **How:** pediatricians and other office staff, monthly from 1986-88, all patients in 4 practices; **Who:** parents of children aged 0-2 years; **Where:** 4 pediatricians' offices in southern California and patient homes.
 - **What:** Community-level (county) policy for surfaces of intervention playgrounds to be covered with pine straw to a depth of 6" in a radius of 9' from every piece of climbing equipment; **How:** county school board policy instituted on 7/1/83; **Who:** children aged 3-9 years; **Where:** all pre-K through elementary schools in 1 county.
 - **What:** Community-level (state) requirement that families provide documentation signed by physician that children received at least 5 doses of DTP vaccine, 4 doses of OPV vaccine, and 1 dose of MMR vaccine prior to kindergarten entry. Children without such documentation were prohibited from attending school; **How:** state law enacted 4/1/82; enforcement began 8/1/82; **Who:** parents of children entering kindergarten; **Where:** Ohio.
 - **What:** Community-level (school) 10-hour education program for resistance to drug use. Curriculum included information about consequences of drug use, correction of beliefs about the prevalence of drug use, counteraction of community norms promoting drug use, practice of pressure resistance, and a public commitment to avoid drug use. Teaching methods included peer teaching, modeling and role playing, and feedback and peer involvement. Course content approved by local PTA and police; **How:** peers (12th grade students with 4 hours of training) and professional health teachers, required class offered each of 3 terms, 1994-95 school year; **Who:** 12th grade students; **Where:** John Doe High School, Peoria, Illinois. **Other:** program implemented as part of a multi-state, multi-component health risk behavior modification program.
2. Did the authors describe the formative research, theoretical basis(es), or construct(s) upon which the intervention was developed? If so, provide as much information as necessary to identify the relevant theory.
 3. What type of organization implemented the intervention (i.e., directly interacted with the population under study, not organizations that might have provided scientific or financial support)? Check all that apply.
 4. Describe any intervention(s) deliberately or inadvertently applied to the comparison or control group(s). **Indicate the page where this information is found.** If the study did not have a comparison or control group, or had a comparison group to which no intervention was applied, skip to question 5.

Examples:

- Families in the comparison group received usual care, which involved a 1-page handout written in English or Spanish describing the potential hazards of deteriorating lead-based paint.
- Families attending the comparison clinic did not receive an intervention as part of the study; however, in Minneapolis and unrelated to the study, during the study period weekly 30-second televised public service announcements were aired encouraging women aged 40 years and over to have annual mammography.

Part II. Descriptive Information

DATA SHEET

A. Description of the Intervention

1. *What:* _____

How: _____

Who: _____

Where: _____

Other: _____

2. Theory described?

Yes *Describe:* _____

No

3. Type of organization (*Check all that apply*)

Managed care organization Public health agency: Federal State Local

Other clinical organization *Specify:* _____

Academic organization

Community-based organization Other governmental agency: Federal State Local

Specify: _____

Other *Specify:* _____

Unknown

Does not apply

4. Interventions for a comparison or control group(s):

No comparison group

No intervention for comparison group (purposefully or inadvertently)

Intervention applied to comparison group *Describe:* _____

B. Evaluation Study Characteristics

(These questions refer specifically to the setting and population that were studied in the evaluation of the intervention.)

Place and Time

5. Location: Where was the **study** done? Specify the city, state, region, etc.
6. Population density: Was the **study** done in an urban, suburban, or rural setting?
 - Check the appropriate box AS DESIGNATED BY THE AUTHORS.
 - Check "**Mixed**" ONLY if the intervention was applied to the entire population of a large geographic area that likely covers urban, suburban, and rural settings.
 - If the authors do not state the population density but do provide ancillary information that allows you to make that determination (e.g., population size, description of the setting, and other community characteristics), use your best judgment to check one of the boxes.
 - If you are unsure about the population density, but the authors report the population size or other information, include that information in the margin without checking one of the boxes.
 - Check "**Not reported**" if the authors do not provide sufficient information about the community to determine the population density.
7. What was the setting in which the intervention was implemented for the purposes of conducting the study? Check all that apply. This might be the same as or a subset of the settings in which the intervention was implemented as described in Part II/Question 1.

Examples:

- *Legislation was implemented state-wide. Check "community-wide" and write in "state."*
 - *An intervention was implemented in schools, shopping malls, and worksites throughout a county. The evaluation of its effectiveness, however, was limited to the schools. Check "schools."*
8. How were outcome and other independent (or predictor) variables measured? Check all that apply. See Part I/Question 3 for relevant outcome measures. **Provide information on observer or interviewer training and blinding, as well as inter-observer agreement as appropriate.**

Response Option	Examples or Definitions
Resource utilization	<i>Hours of media exposure or number of reminders distributed</i>
Observation	Self-explanatory
Interview	Telephone or in-person interview
Self-administered questionnaire	Any written questionnaire that is completed by study participants
Laboratory test	<i>Serum or urine drug levels to assess compliance with drug therapy</i>
Record review	Self-explanatory
Other	
Not reported/Did not assess	Self-explanatory

Example: *The study reported observed correct use of child-restraint devices, using trained but unblinded observers. Inter-observer agreement was performed. Check the response option "Observation" and provide the following: "Correct use defined as child-restraint device tethered to automobile seat with child appropriately harnessed. Observers trained, not blinded. Inter-observer agreement for use = 93% and for estimated age of the child = 83%, $k = .76$, and $.64$, respectively."*

9. Where were outcomes and other variables assessed? If this was the same as the intervention setting, check "same." If different, describe using the same categories as in Part II/Question 7.

Example: *The intervention was implemented in clinics, but measured at observation sites throughout the community. Check "Different from the intervention setting" and write in "community-wide."*
10. Over what time period (include dates) and at what intervals were outcomes and other variables measured?

Example: *The study measured self-reported smoking behavior at 3-month intervals for 2 years after the intervention from January 1986 to December 1987.*

Part II. Descriptive Information

B. Evaluation Study Characteristics

Place/Time

5. Location:
 USA _____
 Other industrialized country _____
 Developing country _____
6. Population density (*Check all that apply*)
 Urban Suburban Rural Mixed Not Reported
7. Setting (*Check all that apply*)
 Hospital Mental health setting Home
 Clinic or health-care provider office Community-based organization Prison
 Nursing home School Street
 Child day care center Workplace Shelter
 Drug treatment facility Religious institution Community-wide
Describe: _____
 Other setting *Specify:* _____
 Does not apply
8. How were outcomes and other independent (or predictor) variables measured?
 Resource utilization *Describe:* _____

 Observation *Describe:* _____

 Interview *Describe:* _____

 Self-administered questionnaire *Describe:* _____

 Laboratory test *Describe:* _____

 Record review *Describe:* _____

 Other *Describe:* _____

 Not reported/Did not assess
9. Where were outcomes measured?
[] Same as intervention setting
[] Different from intervention setting *Describe:* _____

10. Time period and intervals outcome(s) measured? _____

Person (Study Population) (i.e., intervention and comparison populations)

See instructions for question 14 to differentiate the study population from other groups for whom demographic information or results might be reported in the paper.

11a. Describe the eligibility criteria required to enter into the study population.

11b. **For studies in which the investigator allocated** subjects to intervention/comparison groups, describe the groups or individuals who were allocated and the total number eligible for inclusion in the study (N = sampling frame). *Of those eligible*, provide the numbers of groups/or individuals who were allocated. Also provide descriptions of the groups or individuals who were observed and included in analyses and provide the numbers of groups or individuals who were observed and included in analyses. **For observational studies in which the investigators did not allocate intervention and control conditions**, describe the groups or individuals who were observed and included in the analysis; enter NA in the allocation columns for these studies. Many study designs have samples selected or make measurements at multiple points in time; include this information if it is provided. (See first example, below.)

Use the following sampling codes in the columns headed "Samp." under Allocation and Observation:

- E = Entire eligible population**
- P = Probability sample**
- C = Convenience/self-selected sample**
- NR = Not reported**
- NA = Not applicable**

Example: One community received a child-restraint-device distribution program through the community clinic. Neighboring community: no intervention. Mothers of all eligible children in each community interviewed regarding child-restraint-device use when children 3 and 13 months old; all individuals with complete data were included in analysis of the 2 groups.

	Description of groups or individuals N = sampling frame	Allocation				Observation				Number Analyzed	
		Intervention		Comparison		Intervention		Comparison			
		n	Samp.	n	Samp.	n	Samp.	n	Samp.		
Groups	1	Communities N = undefined	1	C	1	C	1	E	1	E	2
	2										
	3										
Individuals		Child MV occupants 3 mo. N = 635 13 mo. N = 510					336 276	E E	214 182	E E	

Example: Investigators conducted a time series analysis on all reports of child motor vehicle crash injuries from a state-wide accident reporting system from 1979 through 1986; a mandatory child-restraint-use law was enacted in 1983. Data were analyzed for all children identified in the database with complete information about injuries and restraint use.

	Description of groups or individuals N = sampling frame	Allocation				Observation				Number Analyzed	
		Intervention		Comparison		Intervention		Comparison			
		n	Samp.	n	Samp.	n	Samp.	n	Samp.		
Groups	1		NA		NA						
	2										
	3										
Individuals		Injured children N = 10,132					5,021	E	5,111	E	10,132

Example: Investigators randomly allocated all 50 clinics serving high-risk populations in a community (of 150 total clinics serving all populations) to either intervention or comparison groups. Intervention clinic physicians were provided with an educational intervention designed to improve vaccination rates. Because of resource constraints, 5 randomly selected clinics in each group were observed for results and analysis. Vaccine coverage was collected from individual patient charts; coverage rates were calculated for the two groups overall (intervention vs. comparison) and grouped by clinic and attending physician.

	Description of groups or individuals N = sampling frame	Allocation				Observation				Number Analyzed	
		Intervention		Comparison		Intervention		Comparison			
		n	Samp.	n	Samp.	n	Samp.	n	Samp.		
Groups	1	Clinics, N = 50	25	E	25	E	5	P	5	P	2 Int v Com 10 clinics
	2	Physicians, N = 22					10	E	12	E	22
	3										
Individuals											

Part II. Descriptive Information

Person (Study Population)

11a. Eligibility criteria: *Describe:* _____

11b. Levels of allocation, observation, and analysis: description and numbers of groups and individuals and methods of sampling. (See instructions for sampling codes to enter in columns headed "Samp.")

	<i>Description of groups or individuals</i> <i>N = sampling frame</i>	<i>Allocation</i>				<i>Observation</i>				<i>Number Analyzed</i>
		<i>Intervention</i>		<i>Comparison</i>		<i>Intervention</i>		<i>Comparison</i>		
		<i>n</i>	<i>Samp.</i>	<i>n</i>	<i>Samp.</i>	<i>n</i>	<i>Samp.</i>	<i>n</i>	<i>Samp.</i>	
<i>Groups</i>										
1										
2										
3										
<i>Individuals</i>										

For designs using follow-up of the study population, calculate the completion rate(s) for the study population:

$$\frac{\text{Number analyzed}}{\text{Number allocated}} \times 100$$

12. How did the investigators assess whether exposure to the intervention actually occurred? See instructions for Part II/Question 8 for additional examples of terms. Provide the definition of the exposure variable(s) as described by the authors and the level of exposure to the intervention. If exposure was different in different subgroups, report the exposure for each group separately. Check all that apply.

Example: Exposure of mothers to a prenatal or postpartum intervention was assessed by resource utilization: 20% of mothers in the community attend prenatal classes at a clinic; 95% of mothers receive a postpartum home visit.

13. Provide all of the requested demographic and risk factor information for the intervention and comparison segments of the study population; **baseline data are preferred**. Provide page/table numbers for this question. Provide information for the study population as a whole **only** if the authors do not report the data for the intervention and comparison groups separately. In this situation, calculate the proportions for the intervention and comparison populations if sufficient information is provided by the authors. If the authors provide only descriptive information about the reference population (i.e., the population from which the study population was drawn) instead of the study population, provide that data (see third example, below). If the authors report demographic and risk factor information for more than four groups, duplicate this page for additional space. For each variable, provide the p value or confidence interval for the difference between groups if available in the last column (enter “NS” if not significant, “NR” if not reported, or “NA” if not applicable).

At the top of each column, describe the group for which you are providing the demographic information.

Examples:

- *The authors implemented an intervention in one school (n = 300 students) and used a second school as a comparison (n = 295); they provided separate demographic information for the intervention and comparison schools. Enter “Intervention school” and “Comparison school” at the tops of the two columns and fill in the appropriate data.*
- *The authors implemented an intervention in one school (n = 300 students) and used a second school as a comparison (n = 295), but only provided demographic information for the two groups as a whole (n = 595). Enter “Entire study population, n = 595” at the top of the column.*
- *The authors implemented an intervention in one school (n = 300 students) and used a second school as a comparison (n = 295), but did not provide demographic information for the students participating in the study. Instead, the authors describe the demographics of the community in which the schools are located. Enter “Reference population only” and any descriptive information about the community for which data are provided.*

Age: Provide median/range, mean/standard deviation, other measure of central tendency or “not reported.” If categories are used, provide the categories and the percent of the study population in each category. If a proxy for age such as school grade is presented, indicate the range and the units.

Sex: Provide the percent male, female, and/or unknown; or “not reported”

Race/Ethnicity: Provide the percentage for each race/ethnic group or check “not reported” if the authors do not provide this information. If information is provided for part of the population, but not reported for some proportion, check all that apply including the “Other/Unknown” category and specify the proportion unknown. If information is unknown, circle “Unknown”; if the response is other, circle “Other” and specify.

Socioeconomic status: Check “low,” or “middle/upper,” **as reported by the authors** or “not reported.” Use reasonable judgement to select a category if the authors provide ancillary information (e.g., educational attainment).

Other: Provide any other demographic or risk factor information reported by the authors.

Examples: migrant status, educational attainment, occupation, risk behavior categories (e.g., men who have sex with men, drivers with criminal convictions for alcohol-impaired driving), and other potential confounding factors.

Part II. Descriptive Information

12. Assessment of exposure to the intervention. Provide the definition of each exposure variable and the level of exposure in the space provided for each.

- Resource utilization *Describe:* _____
- Observation *Describe:* _____
- Interview *Describe:* _____
- Self-administered questionnaire *Describe:* _____
- Laboratory test *Describe:* _____
- Record review *Describe:* _____
- Other *Describe:* _____
- Not reported/Did not assess

13. Study population demographics:

	Group:	Group:	Group:	Group:	P value or CI
Age	_____	_____	_____	_____	
	<input type="checkbox"/> Not reported	<input type="checkbox"/> Not reported	<input type="checkbox"/> Not reported	<input type="checkbox"/> Not reported	
Sex	_____ % male	_____ % male	_____ % male	_____ % male	
	_____ % female	_____ % female	_____ % female	_____ % female	
	_____ % unknown	_____ % unknown	_____ % unknown	_____ % unknown	
	<input type="checkbox"/> Not reported	<input type="checkbox"/> Not reported	<input type="checkbox"/> Not reported	<input type="checkbox"/> Not reported	
Race (%)	<input type="checkbox"/> Not reported	<input type="checkbox"/> Not reported	<input type="checkbox"/> Not reported	<input type="checkbox"/> Not reported	
<input type="checkbox"/> American Indian or Alaska Native	_____ %	_____ %	_____ %	_____ %	
<input type="checkbox"/> Asian	_____ %	_____ %	_____ %	_____ %	
<input type="checkbox"/> Black or African American	_____ %	_____ %	_____ %	_____ %	
<input type="checkbox"/> Native Hawaiian or Other Pacific Islander	_____ %	_____ %	_____ %	_____ %	
<input type="checkbox"/> White	_____ %	_____ %	_____ %	_____ %	
<input type="checkbox"/> Other/Unknown <i>Specify:</i>	_____ :	_____ :	_____ :	_____ :	
	_____ %	_____ %	_____ %	_____ %	
Ethnicity (%)	<input type="checkbox"/> Not reported	<input type="checkbox"/> Not reported	<input type="checkbox"/> Not reported	<input type="checkbox"/> Not reported	
<input type="checkbox"/> Hispanic or Latino	_____ %	_____ %	_____ %	_____ %	
<input type="checkbox"/> Not Hispanic or Latino	_____ %	_____ %	_____ %	_____ %	
<input type="checkbox"/> Other/Unknown <i>Specify:</i>	_____ :	_____ :	_____ :	_____ :	
	_____ %	_____ %	_____ %	_____ %	
Socioeconomic status	<input type="checkbox"/> Low	<input type="checkbox"/> Low	<input type="checkbox"/> Low	<input type="checkbox"/> Low	
	<input type="checkbox"/> Middle/upper	<input type="checkbox"/> Middle/upper	<input type="checkbox"/> Middle/upper	<input type="checkbox"/> Middle/upper	
	<input type="checkbox"/> Not reported	<input type="checkbox"/> Not reported	<input type="checkbox"/> Not reported	<input type="checkbox"/> Not reported	
Other population demographic and risk factor characteristics <i>Specify:</i>	_____	_____	_____	_____	
	_____	_____	_____	_____	
	_____	_____	_____	_____	
	_____	_____	_____	_____	
	_____	_____	_____	_____	
	_____	_____	_____	_____	

14. Some interventions are directed at a specific study population, but ultimately affect health or other related outcomes (e.g., behaviors) that are measured in a different population. For example, a provider education intervention is directed at health care providers (the “study population”), but the health outcome occurs in their patients (the “ultimately affected” population). Another example is when an educational intervention directed at parents (the “study population”) ultimately affects their children (the “ultimately affected” population). **Does this study report demographic information for or measure an outcome in a population of persons who were ultimately affected by the intervention applied to the study population?** If no, skip to question 18.

Examples:

- *A professional education intervention about the indications and contraindications for childhood immunizations was administered to half of the physicians in a group practice (the other half served as controls). The researchers measured vaccine coverage rates in the children served by the practice. The researchers presented demographic information for the physicians (i.e., the study population) AND for the children (i.e., the ultimately affected population). Report the demographic information for the physicians in question 13 and for the children in questions 14-17.*
- *If the intervention was implemented in and the effects measured in the same group of people, the answer to this question is “no.”*

15. How many groups were in the “ultimately affected” population?
16. Indicate the number of members in each of the “ultimately affected” population groups, and describe those members.
17. Provide all of the requested demographic information for the “ultimately affected” population. See instructions for Part II/Question 13 for details.

Part II. Descriptive Information

14. "Ultimately affected" population described or outcomes reported?
 Yes (Go to question 15) No (Go to question 18)

15. Number of groups in the "ultimately affected" population? _____

16. Number and description of members in each group: _____

17. "Ultimately affected" population demographics:

	Group:	Group:	P value or CI
Age	_____ _____ _____ <input type="checkbox"/> Not reported	_____ _____ _____ <input type="checkbox"/> Not reported	
Sex	_____% male _____% female _____% unknown <input type="checkbox"/> Not reported	_____% male _____% female _____% unknown <input type="checkbox"/> Not reported	
Race (%)	<input type="checkbox"/> Not reported	<input type="checkbox"/> Not reported	
<input type="checkbox"/> American Indian or Alaska Native	_____%	_____%	
<input type="checkbox"/> Asian	_____%	_____%	
<input type="checkbox"/> Black or African American	_____%	_____%	
<input type="checkbox"/> Native Hawaiian or Other Pacific Islander	_____%	_____%	
<input type="checkbox"/> White	_____%	_____%	
<input type="checkbox"/> Other/Unknown <i>Specify:</i>	_____ _____%	_____ _____%	
Ethnicity (%)	<input type="checkbox"/> Not reported	<input type="checkbox"/> Not reported	
<input type="checkbox"/> Hispanic or Latino	_____%	_____%	
<input type="checkbox"/> Not Hispanic or Latino	_____%	_____%	
<input type="checkbox"/> Other/Unknown <i>Specify:</i>	_____ _____%	_____ _____%	
Socioeconomic status	<input type="checkbox"/> Low <input type="checkbox"/> Middle/upper <input type="checkbox"/> Not reported	<input type="checkbox"/> Low <input type="checkbox"/> Middle/upper <input type="checkbox"/> Not reported	
Other population demographic and risk factor characteristics <i>Specify:</i>	_____ _____ _____ _____	_____ _____ _____ _____	

C. Results

18. Primary study results: From Part I/Question 3 of this form, describe each of the primary outcome measures used in this study and the effect measure as reported by the author. Indicate the table number (in the paper) from which the data are taken, if applicable. For each outcome measure, report the results for each arm of the intervention group (as applicable) and for each of the comparison groups (as applicable); report the results for each time period measured as applicable to the study design (i.e., before and after the intervention, only after the intervention, for each time period in a time series design). Fill in the time periods as shown.

Examples:

Outcome measure (List from Part I/Question 3 and describe effect measure in numbered row)	Effect size reported by authors						Software used, hypothesis testing, p values, CI, etc.
	Studies with pre - post measurements		Studies with multiple measurements over time				
	Pre Oct 77	Post Oct 78	Time 1 Mar 80	Time 2 Apr 80	Time 3 May 80	Time 4 Jun 80	
1a. Prevalence rates of self-reported child restraint device use (baseline rate is pre-intervention rate [Oct '77] for comparison group). Table 3, page 22 in the paper.							<i>Intervention arm 1 versus comparison: $\chi^2 = xx, p = xx$</i> <i>Intervention arm 2 versus comparison: $\chi^2 = xx, p = xx$</i>
Intervention Arm 1	50%	75%					
Intervention Arm 2	45%	68%					
Intervention Arm 3							
Comparison Group 1	50%	50%					
Comparison Group 2							
Comparison Group 3							
1b. Validation of 1a using observed rates of child restraint device use (baseline rate is pre-intervention rate [Oct '77] for comparison group). Table 2, page 22 in the paper.							<i>Intervention arm 1 versus comparison: $\chi^2 = xx, p = xx$</i> <i>Intervention arm 2 versus comparison: $\chi^2 = xx, p = xx$</i>
Intervention Arm 1	49%	70%					
Intervention Arm 2	49%	62%					
Intervention Arm 3							
Comparison Group 1	45%	53%					
Comparison Group 2							
Comparison Group 3							
2. Vaccine coverage rates for children over time (March '80 = baseline rate, intervention applied before time 2; no comparison group). Table 1, page 1543 in the paper.							<i>SAS (Proc freq) Change in intervention group time 4 versus time 1 (baseline): $\chi^2 = xx, p = xx$</i>
Intervention Arm 1			44%	46%	76%	56%	
Intervention Arm 2							
Intervention Arm 3							
Comparison Group 1							
Comparison Group 2							
Comparison Group 3							
3. Percent of students self-reporting drinking and driving. Table 3, page 29 in paper.							<i>EpiInfo Intervention arm 1 versus comparison: $\chi^2 = xx, p = xx$</i> <i>Intervention arm 2 vs comparison: $\chi^2 = xx, p = xx$</i>
Intervention Arm 1	NA	13%					
Intervention Arm 2	NA	16%					
Intervention Arm 3							
Comparison Group 1	NA	29%					
Comparison Group 2							
Comparison Group 3							

19. Did the authors conduct a power analysis, discuss other statistical procedures, or cite other literature to determine the appropriate sample size PRIOR to implementation of the intervention? If no, **IN YOUR OPINION**, was the sample size sufficient to find the desired effect? Provide a brief justification of this determination.

Example: Study included interviews with 98% of women with live births in 2 communities and conducted follow-up with 80% of the original study population. Sample sufficient to find a relatively small effect.

Part II. Descriptive Information

C. Results

18. Primary study results.

Outcome measure (List from Part I/Question 10 and describe effect measure in numbered row)	Effect size reported by authors						Software used, hypothesis testing, p values, CI, etc.
	Studies with pre - post measurements		Studies with multiple measurements over time				
	Pre	Post	Time 1	Time 2	Time 3	Time 4	
1.							
Intervention Arm 1							
Intervention Arm 2							
Intervention Arm 3							
Comparison Group 1							
Comparison Group 2							
Comparison Group 3							
2.							
Intervention Arm 1							
Intervention Arm 2							
Intervention Arm 3							
Comparison Group 1							
Comparison Group 2							
Comparison Group 3							
3.							
Intervention Arm 1							
Intervention Arm 2							
Intervention Arm 3							
Comparison Group 1							
Comparison Group 2							
Comparison Group 3							
4.							
Intervention Arm 1							
Intervention Arm 2							
Intervention Arm 3							
Comparison Group 1							
Comparison Group 2							
Comparison Group 3							

19. Power calculation, other statistical analysis, or citation?

Yes

No; was sample size sufficient? (Justification): _____

20. Were secondary results of interest reported (including subpopulation differences, dose-response relationships, or others)? If yes, describe those results. Include page and table numbers.

Examples:

- *The effect was stronger among African-American children (the postcard reminder resulted in 70% of children being up to date on immunizations at age 2 years compared to 20% of children who received "usual care.")*
- *The intervention had less effect among white children where 40% of children who did and did not receive the intervention were up to date on immunizations at age 2 years).*

D. Feasibility and Other Key Issues Addressed in the Paper

21. Which of the following feasibility and other key issues were addressed in the paper? To flag issues that might be of importance in describing the intervention or its implementation, check off any of the following issues that are described by the authors. This will assist the chapter development team in quickly identifying papers that address these issues. Check all that apply. **Include the page numbers where this information can be found in the paper.**

- Costs of the intervention (include monetary, nonmonetary or human resources)
- Potential harms of the intervention (includes health and social consequences)
- Other benefits
- Implementation of the intervention
- Barriers to implementation
- Community acceptance or involvement in development or implementation of the intervention
- Formation or use of existing coalitions to develop, implement, or evaluate interventions
- Ethical constraints
- Other
- Not discussed (i.e., no other data were presented)

22. In the space provided, include any other information that you feel we should be aware of or that will aid you in evaluating the quality of the intervention in the next section of this form. **Example:** *Some evaluations may be able to measure how the intervention was monitored (e.g., fidelity, quality assurance). Describe such efforts here.*

23. Identify references from the reference list that might be related to the particular intervention, subtopic, or topic that is the focus of this review. Provide this information by circling or highlighting the relevant references directly on a photocopy of the references pages from the paper and returning it with this form or by listing the reference numbers (or the author and year) from the reference list in the space provided.

Example: *During a review about the effectiveness of patient reminders in improving vaccine coverage, a reference about patient reminders to improve measles vaccine coverage would be directly relevant, but references about efficacy of vaccine or effectiveness of community education in improving vaccine coverage, or about burden of measles disease in the U.S. would not be directly relevant.*

Part II. Descriptive Information

DATA SHEET

20. Secondary results Yes Not reported

If yes, specify: _____

E. Feasibility and Other Key Issues Addressed in the Paper

21. Costs
 Potential harms
 Other benefits
 Implementation
 Barriers to implementation
 Community acceptance or involvement
 Formation or use of existing coalitions to develop, implement, or evaluate interventions
 Ethical constraints
 Other Describe: _____
 Not discussed

22. Other important information:

23. Relevant references:

This page was intentionally left blank.

Part III: Study Quality Instructions

Study quality is evaluated using six categories of common problems (Descriptions, Sampling, Measurement, Analysis, Interpretation of Results, and Other). Study validity poses a complex problem when evaluating the quality of studies. It is possible that elements of each of the six categories contribute to problems with study validity. Therefore, we have tried to elicit information in each category that may contribute to poor study validity which potentially limit our ability to interpret the results of the study.

Some problems with a study can be included under several of the categories. Use your best judgement to list the problem under the **MOST** appropriate category.

Example: Students at schools that had an intensive educational program to reduce drug use could have been less likely than other students to report drug use (independent of actual use). This problem could be marked as a limitation of this study under the category “Measurement” because of problems with the validity and reliability of self-reported outcomes. Alternatively, this problem could be marked as a limitation of the study under the category “Interpretation of Results” because of poor randomization, other activities ongoing in the schools, uncontrolled differences in the intervention and comparison populations prior to implementation of the intervention, etc. **The reviewer must decide if one or both of these categories are limited based on the information provided in the paper. If questions arise, err on the side of providing more information and checking the maximum number of categories.**

The relative merits of different study designs will be considered separately from the quality of execution of the study. **Thus, given that the study you reviewed has a particular study design (Part I/Question 1), answer these questions based on the quality of execution of this study’s design, NOT whether this was the best possible study design that could have been used.**

One or more questions are posed for each category. Each question is designed to elicit information about potential limitations in the quality of a study. In the column to the right of each question, the numbers corresponding to items in Part II of this form relevant to answering that question are provided. Answers that suggest quality limitations are labeled “limitation.” **Potential quality limitations for a question should be noted if they are of sufficient magnitude to diminish your confidence in the results.**

Briefly explain each of your assessments in the space provided; **always provide comments for limitations of a question.** If possible, the impact of the limitation on the results should be estimated. (e.g., a study in which many members of the control group received an intervention that was similar to that offered to the intervention group would probably underestimate any reported effect of the intervention).

Note: When it appears as a response option, N/A=Not Applicable.

EXPLAIN ALL ASSESSMENTS!

1. Descriptions	Related Questions
<p>A. Was the study population (i.e., the intervention and comparison population) well described? The study population should be described by time (e.g., when the study population received the intervention), place, and person. Information about “person” should include at least age (for all studies) and should include other relevant characteristics of participants that are key to a particular study (e.g., <i>SES, gender, other</i>). Important potential confounding factors should also be described.</p>	II/1, 5, 6, 11a/b, 13
<p>B. Was the intervention well described? The intervention should be described in terms of what was done, how it was delivered, who was targeted, and where it was done.</p>	II/1, 2, 3, 4
2. Sampling	Related Questions
<p>A. Did the authors specify (i.e., describe characteristics and size of) the sampling frame or universe of selection for the study population?</p>	II/1, 11b
<p>B. Did the authors specify the screening criteria for study eligibility (if applicable)?</p>	II/1, 11a
<p>C. Was the population that served as the unit of analysis the entire eligible population or a probability sample at the point of observation?</p>	II/11b
<p>To answer this question follow these steps:</p>	
<p>1. Using question 11b in Part II (page 4) refer to the column “Number analyzed” to identify the unit(s) of analysis(es).</p>	
<p>2. The question refers to the sampling method (“Samp.”) under the column labeled “Observation” for that unit of analysis. If the sampling method is “E” or “P” the answer to this question is “Yes;” otherwise, the answer to this question is “No.”</p>	
<p>D. Are there other selection bias issues not identified above? This might include a very low participation rate (or a high refusal rate), an all-volunteer sample (as opposed to a convenience sample selected by the investigators), an inappropriate control or comparison group, or extremely restricted sampling inappropriate for measuring the effectiveness of the intervention being studied.</p>	II/11a/b

EXPLAIN ALL ASSESSMENTS!

1. Descriptions	Yes	No	Related Questions
A. Was the study population well described?	<input type="checkbox"/>	<input type="checkbox"/>	II/1, 5, 6, 11a/b, 13
B. Was the intervention well described (what, how, who, where)?	<input type="checkbox"/>	<input type="checkbox"/>	II/1, 2, 3, 4
<i>Explain:</i>			

2. Sampling	Yes	No	N/A	Related Questions
A. Did the authors specify the sampling frame or universe of selection for the study population?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	II/1, 11b
B. Did the authors specify the screening criteria for study eligibility?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	II/1, 11a
C. Was the population that served as the unit of analysis the entire eligible population or a probability sample at the point of observation?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	II/11b
D. Are there other selection bias issues not otherwise addressed? Describe.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	II/11a/b
<i>Explain:</i>				

DID YOU PROVIDE COMMENTS FOR ALL ASSESSMENTS?

3. Measurement	Related Questions
A. Was there an attempt to measure exposure to the intervention? (If NA or No, go to 3C)	II/12
B. Were the exposure variables valid measures of the intervention under study? The authors should have reported one or more of the following: <ul style="list-style-type: none"> • Clear definition of the exposure variable. • Measurement of exposure in different ways. <i>Example: consistency checks for self reports; use of corroborating respondents; program or organizational record searches compared to self-reports.</i> • Citations or discussion as to why the use of these measures is valid. <i>Example: the authors considered evidence from similar studies, or available standards of measurement.</i> • Other <p>Were the exposure variables reliable (consistent and reproducible) measures of the intervention under study? The authors should have reported one or more of the following:</p> <ul style="list-style-type: none"> • Measures of internal consistency. <i>Example: Cronbach's alpha; confirmatory factor analysis.</i> • Measurement of exposure in different ways. <i>Example: see above.</i> • Inter-rater reliability checks (if exposure was determined by an observer). <i>Example: percent agreement, Kappa</i> • Citations or discussion as to why the use of these measures is reliable. <i>Example: see above</i> • Other 	II/12
C. Were the outcome and other independent (or predictor) variables valid measures of the outcome of interest? The authors should have reported one or more of the following: <ul style="list-style-type: none"> • Clear definition of the outcome variable. • Measurement of the outcome in different ways. <i>Example: Correlational analysis between measured outcomes to demonstrate convergent (i.e., 2 or more measures reflect the same underlying process) or divergent validity (i.e., 2 or more measures reflect different dimensions). An example of the former is that 5 items on self-efficacy correlate highly with each other; an example of the latter is that self-efficacy measures do not correlate highly with attitude measures.</i> • Citations or discussion as to why the use of these measures is valid. <i>Example: see above</i> • Other. <i>Example: If authors fail to blind observers/interviewers to treatment vs. comparison group, when applicable, the answer to this question should be "no."</i> <p>Were the outcome and other independent (or predictor) variables reliable (consistent and reproducible) measures of the outcome of interest?</p> <p>The authors should have reported one or more of the following:</p> <ul style="list-style-type: none"> • Measures of internal consistency. <i>Example: see 3B</i> • Measurement of the outcome in different ways. <i>Example: see 3B and 3C (above).</i> • Considered consistency of coding, scoring or categorization between observers (e.g., inter-rater reliability checks) or between different outcome measures. <i>Example: percent agreement, Kappa</i> • Considered how setting and sampling of study population might affect reliability. • Citations or discussion as to why the use of these measures is reliable. <i>Example: see 3B.</i> • Other 	I/10
D. Were the outcome and other independent (or predictor) variables reliable (consistent and reproducible) measures of the outcome of interest?	II/8, 9 10, 18, 20
The authors should have reported one or more of the following:	
• Measures of internal consistency. <i>Example: see 3B</i>	
• Measurement of the outcome in different ways. <i>Example: see 3B and 3C (above).</i>	
• Considered consistency of coding, scoring or categorization between observers (e.g., inter-rater reliability checks) or between different outcome measures. <i>Example: percent agreement, Kappa</i>	
• Considered how setting and sampling of study population might affect reliability.	
• Citations or discussion as to why the use of these measures is reliable. <i>Example: see 3B.</i>	
• Other	
4. Data analysis	Related Questions
A. Check "yes," "no," or "not applicable" for each of the following:	
Did the authors conduct appropriate analysis by:	
• Conducting statistical testing (when appropriate)?	II/18, 20
• Reporting which statistical tests were used?	II/18, 20
• Controlling for design effects in the statistical model?	II/18, 20
Examples:	
1. <i>The study population was sampled using complex stratified sampling, however, the authors did not control for the sampling method in the analysis.</i>	
2. <i>The answer should be "no" if the study had a matched design but an unmatched analysis.</i>	
• Controlling for repeated measures in the analysis, for study designs in which the same population was followed with repeated measurements over time?	II/18, 20
• Accounting for different levels of exposure in segments of the study population in the analysis?	II/12
• If the authors analyzed group-level and individual-level covariates in the same statistical model, was the model designed to handle multi-level data?	II/1, 11b
B. Were there other problems with data analysis that limit interpretation of the results of the study? Specify.	II/18, 20

EXPLAIN ALL ASSESSMENTS!

3. Measurement	Yes	No	N/A	Related Questions
A. Did the authors attempt to measure exposure to the intervention?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	II/12
	go to 3B	go to 3C	go to 3C	
B. Was the exposure variable:				
• Valid?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	II/12
• Reliable (consistent and reproducible)?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	II/12
C. Were the outcome and other independent (or predictor) variables:				
• Valid?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	I/10
• Reliable (consistent and reproducible)?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	II/8, 9 10, 18, 20
<i>Explain:</i>				

4. Data Analysis	Yes	No	N/A	Related Questions
A. Did the authors conduct appropriate statistical testing by:				
• Conducting statistical testing (when appropriate)?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	II/18, 20
• Reporting which statistical tests were used?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	II/18, 20
• Controlling for design effects in the statistical model?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	II/18, 20
• Controlling for repeated measures in populations that were followed over time?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	II/18, 20
• Controlling for differential exposure to the intervention?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	II/12
• Using a model designed to handle multi-level data when they included group-level and individual covariates in the model?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	II/1, 11b
B. Are there other problems with the data analysis? Describe.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	II/18, 20
<i>Explain:</i>				

DID YOU PROVIDE COMMENTS FOR ALL ASSESSMENTS?

5. Interpretation of Results	Related Questions
<p>A. Did at least 80% of enrolled participants (i.e., intervention AND comparison groups) complete the study? This may be reported as a “lost-to-follow-up” or “drop-out” rate. If the authors did not report >80% follow-up but conducted an alternative analysis that concluded that the high attrition did not influence the results of the study, check “yes.”</p> <p>For many study designs, this criterion is not applicable (i.e., time series, before-after designs with or without a concurrent comparison group, surveys); for these studies, check the response option “Not Applicable.”</p>	II/11a/b, 18, 20
<p>B. Confounding:</p> <ul style="list-style-type: none"> • Did the authors assess whether the units of analyses were comparable prior to exposure to the intervention? For example, they should have assessed likely confounding via report of p values and confidence intervals for the descriptive variables of age and sex or other key individual/community characteristics. II/13 • Considering the study design, were appropriate methods for controlling confounding variables and limiting potential biases used? Confounding can be addressed by appropriate use of randomization, restriction, matching, stratification, or multivariable methods. Sometimes use of a single method may be inadequate. Some biases can be limited by institution of data collection or study procedures that support validity of the study (e.g. training and/or blinding of interviewers or observers, interviewers and observers are different from intervention implementors, etc.) I/8; II/11b, 18, 20; III/6A <p><i>Example: If between-group differences persist after randomization or matching, statistical control should also have been used.</i></p>	
<p>C. Biases:</p> <p>Did the authors identify and discuss potential biases or unmeasured/contextual confounders that may account for or influence the observed results and explicitly state how they assessed these potential confounders and biases? Please describe these factors and, if possible, comment on the likely direction of bias. If there are additional biases NOT COVERED IN OTHER CATEGORIES that the authors did not address, please list these as well.</p> <p>Examples:</p> <ol style="list-style-type: none"> 1. <i>A time series study of an intervention intended to enhance immunization delivery during a period of considerable attention to immunizations could incorrectly attribute increases in vaccine coverage to the intervention under study and thus overestimate the effect of the intervention.</i> 2. <i>A study of an educational program to improve levels of physical activity during a period when the control group was also likely to receive considerable education about physical activity could under-estimate the effectiveness of the program.</i> 	
6. Other	
<p>Are there other issues that limit your ability to interpret the results of the study that were not identified handled in one of the other categories? Please limit your comments in this box to those limitations of the study that cannot be evaluated in other categories, and for which you can make a detailed justification. If you have a concern but are not able to clearly state why it should be a limitation of the study, contact the staff scientist to discuss the issue.</p>	

* Many excellent epidemiology and evaluation texts describe biases inherent in different study designs. For a concise list and definitions of various biases, refer to:

A dictionary of epidemiology. 2nd Edition. Last JM, ed. New York, New York: Oxford University Press, 1988.

EXPLAIN ALL ASSESSMENTS!

5. Interpretation of Results	Yes	No	N/A	Cross-Reference
A. Did at least 80% of enrolled participants complete the study?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	II/11a/b, 18, 20
B. Did the authors assess:				
• Whether the units of analyses were comparable prior to exposure to the intervention?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	II/13
• Correct for controllable variables or institute study procedures to limit bias appropriately (e.g., randomization, restriction, matching, stratification, or statistical adjustment)?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	I/8; II/11b, 18, 20; III/6A

Explain:

C. Check “yes” and describe all potential biases or unmeasured/contextual confounders described by the authors. You may also check “no” and describe other potential biases or unmeasured/contextual confounders NOT identified by the authors. For all responses, indicated the likely direction of effect on the results, if possible.	Yes	No
	<input type="checkbox"/>	<input type="checkbox"/>

authors:


reviewer:

6. Other

Other important limitations of the study **not** identified elsewhere (specify):

DID YOU PROVIDE COMMENTS FOR ALL ASSESSMENTS?

Figure. Study Design Algorithm



Reprinted by permission of Elsevier Science from:
Data Collection Instrument and Procedure for Systematic Reviews in
the Guide to Community Preventive Services. Stephanie Zaza, Linda
Wright-DeAguero, Peter A. Briss et al., American Journal of
Preventive Medicine, Vol 18 No 1S, pp 44-74, Copyright 2000 by
American Journal of Preventive Medicine